Liver abnormalities in pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is a cardiopulmonary disease with high mortality. In recent years, it has been recognized that PAH is a multi-organ system disease, involving the systemic circulation, kidneys, skeletal muscles, and the central nervous system, among others. Right heart failure p...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Nils P. Nickel, Gian M. Galura, Marc J. Zuckerman, M. Nawar Hakim, Haider Alkhateeb, Debabrata Mukherjee, Eric D. Austin, Gustavo A. Heresi
Format: article
Langue:EN
Publié: SAGE Publishing 2021
Sujets:
Accès en ligne:https://doaj.org/article/8ff5dbda5de746daa6ac14ecc0538b4f
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Description
Résumé:Pulmonary arterial hypertension (PAH) is a cardiopulmonary disease with high mortality. In recent years, it has been recognized that PAH is a multi-organ system disease, involving the systemic circulation, kidneys, skeletal muscles, and the central nervous system, among others. Right heart failure produces congestive hepatopathy, a disease state that has direct consequences on liver biochemistry, histology, and systemic glucose and lipid metabolism. This article aims to summarize the consequences of congestive hepatopathy with an emphasis on liver biochemistry, histology, and PAH-targeted therapy. Furthermore, PAH-specific changes in glucose and lipid metabolism will be discussed.